Marijana Kovačić1, Olivera Mitrović-Ajtić1, Bojana Beleslin-Čokić2, Dragoslava Djikić1, Tijana Subotički1, Miloš Diklić1, Danijela Leković3, Mirjana Gotić3,4, Pascal Mossuz5, Vladan P Čokić6. 1. Department of Molecular Oncology, Institute for Medical Research, University of Belgrade, Dr. Subotica 4, Belgrade, 11129, Serbia. 2. Clinic for Endocrinology, Diabetes and Metabolic Diseases, Genetic laboratory, Clinical Center of Serbia, Belgrade, Serbia. 3. Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia. 4. Medical Faculty, University of Belgrade, Belgrade, Serbia. 5. Département d'Hématologie, Institut de Biologie et Pathologie, CHU Grenoble, Grenoble, France. 6. Department of Molecular Oncology, Institute for Medical Research, University of Belgrade, Dr. Subotica 4, Belgrade, 11129, Serbia. vl@imi.bg.ac.rs.
Abstract
PURPOSE: Previously, the family of S100A proteins has been found to be associated with inflammation and myelopoiesis and to be able to induce or support myeloproliferation during chronic inflammation. Here, we studied the inflammatory myeloid-related proteins S100A4, S100A8, S100A9 and S100A12 in myeloproliferative neoplasms (MPNs) in order to assess the involvement of chronic inflammation in the pathogenesis of MPN. METHODS: We analyzed the S100A4, S100A8, S100A9 and S100A12 mRNA and protein levels in the bone marrow and circulation of 140 patients with MPN and 15 healthy controls using Western blotting, microarray-based mRNA expression profiling and ELISA assays, respectively. In addition we performed functional studies on the proliferation-related AKT and ERK1/2 signaling pathways in MPN-derived granulocytes using Western blotting and proteomic analyses. RESULTS: We found that the S100A mRNA levels were increased in MPN patient-derived circulatory CD34+ cells, and that their protein expression levels were also augmented in their granulocytes and bone marrow stroma cells, depending on the JAK2V617F mutation allele burden. We also found that calreticulin (CALR) mutations were related to reduced S100A8 plasma levels in primary myelofibrosis (PMF). The S100A8 plasma levels were found to be increased in MPN, the S100A9 plasma levels in PMF and essential thrombocythemia (ET), and the S100A12 plasma levels in polycythemia vera (PV). These S100A plasma levels showed a positive correlation with the systemic inflammation marker IL-8, as well as with the numbers of leukocytes and thrombocytes, depending on the JAK2V617F mutation status. Additionally, we found that heterodimeric S100A8/9 can inhibit the AKT pathway in MPN-derived granulocytes mediated by the Toll-like receptor 4 (TLR4), depending on the CALR mutation status. Conversely, we found that blocking of the receptor for advanced glycation end products (RAGE) increased the S100A8/9-mediated inhibition of AKT signaling in the MPN-derived granulocytes. Moreover, we found that heterodimeric S100A8/9 generally induced TLR4-mediated ERK1/2 dephosphorylation proportionally to the JAK2V617F mutation allele burden. TLR4/RAGE blocking prevented the S100A8/9-mediated inhibition of ERK1/2 phosphorylation in PV. CONCLUSIONS: From our data we conclude that the S100A8 and S100A9 granulocyte and plasma levels are increased in MPN patients, along with inflammation markers, depending on their JAK2V617F mutation allele burden. We also found that S100A8/9-mediated inhibition of the proliferation-related AKT and ERK1/2 signaling pathways can be decreased by CALR mutation-dependent TLR4 blocking and increased by RAGE inhibition in MPN.
PURPOSE: Previously, the family of S100A proteins has been found to be associated with inflammation and myelopoiesis and to be able to induce or support myeloproliferation during chronic inflammation. Here, we studied the inflammatory myeloid-related proteins S100A4, S100A8, S100A9 and S100A12 in myeloproliferative neoplasms (MPNs) in order to assess the involvement of chronic inflammation in the pathogenesis of MPN. METHODS: We analyzed the S100A4, S100A8, S100A9 and S100A12 mRNA and protein levels in the bone marrow and circulation of 140 patients with MPN and 15 healthy controls using Western blotting, microarray-based mRNA expression profiling and ELISA assays, respectively. In addition we performed functional studies on the proliferation-related AKT and ERK1/2 signaling pathways in MPN-derived granulocytes using Western blotting and proteomic analyses. RESULTS: We found that the S100A mRNA levels were increased in MPN patient-derived circulatory CD34+ cells, and that their protein expression levels were also augmented in their granulocytes and bone marrow stroma cells, depending on the JAK2V617F mutation allele burden. We also found that calreticulin (CALR) mutations were related to reduced S100A8 plasma levels in primary myelofibrosis (PMF). The S100A8 plasma levels were found to be increased in MPN, the S100A9 plasma levels in PMF and essential thrombocythemia (ET), and the S100A12 plasma levels in polycythemia vera (PV). These S100A plasma levels showed a positive correlation with the systemic inflammation marker IL-8, as well as with the numbers of leukocytes and thrombocytes, depending on the JAK2V617F mutation status. Additionally, we found that heterodimeric S100A8/9 can inhibit the AKT pathway in MPN-derived granulocytes mediated by the Toll-like receptor 4 (TLR4), depending on the CALR mutation status. Conversely, we found that blocking of the receptor for advanced glycation end products (RAGE) increased the S100A8/9-mediated inhibition of AKT signaling in the MPN-derived granulocytes. Moreover, we found that heterodimeric S100A8/9 generally induced TLR4-mediated ERK1/2 dephosphorylation proportionally to the JAK2V617F mutation allele burden. TLR4/RAGE blocking prevented the S100A8/9-mediated inhibition of ERK1/2 phosphorylation in PV. CONCLUSIONS: From our data we conclude that the S100A8 and S100A9 granulocyte and plasma levels are increased in MPN patients, along with inflammation markers, depending on their JAK2V617F mutation allele burden. We also found that S100A8/9-mediated inhibition of the proliferation-related AKT and ERK1/2 signaling pathways can be decreased by CALR mutation-dependent TLR4 blocking and increased by RAGE inhibition in MPN.
Authors: Ilyas Chachoua; Christian Pecquet; Mira El-Khoury; Harini Nivarthi; Roxana-Irina Albu; Caroline Marty; Vitalina Gryshkova; Jean-Philippe Defour; Gaëlle Vertenoeil; Anna Ngo; Ann Koay; Hana Raslova; Pierre J Courtoy; Meng Ling Choong; Isabelle Plo; William Vainchenker; Robert Kralovics; Stefan N Constantinescu Journal: Blood Date: 2015-12-14 Impact factor: 22.113
Authors: Philipp Ehlermann; Kai Eggers; Angelika Bierhaus; Patrick Most; Dieter Weichenhan; Johannes Greten; Peter P Nawroth; Hugo A Katus; Andrew Remppis Journal: Cardiovasc Diabetol Date: 2006-03-30 Impact factor: 9.951
Authors: Julian Baumeister; Tiago Maié; Nicolas Chatain; Lin Gan; Barbora Weinbergerova; Marcelo A S de Toledo; Jörg Eschweiler; Angela Maurer; Jiri Mayer; Blanka Kubesova; Zdenek Racil; Andreas Schuppert; Ivan Costa; Steffen Koschmieder; Tim H Brümmendorf; Deniz Gezer Journal: Ann Hematol Date: 2021-08-14 Impact factor: 4.030
Authors: Ji-Sook Lee; Na Rae Lee; Ayesha Kashif; Seung-Ju Yang; A Reum Nam; Ik-Chan Song; Soo-Jung Gong; Min Hwa Hong; Geunyeong Kim; Pu Reum Seok; Myung-Shin Lee; Kee-Hyung Sung; In Sik Kim Journal: Front Immunol Date: 2020-08-06 Impact factor: 7.561
Authors: Alexandre Carvalho; Jacky Lu; Jamisha D Francis; Rebecca E Moore; Kathryn P Haley; Ryan S Doster; Steven D Townsend; Jeremiah G Johnson; Steven M Damo; Jennifer A Gaddy Journal: Gastroenterol Res Pract Date: 2020-02-26 Impact factor: 2.260